Market
Primary reason for Ozempic prescription increase in Europe post-EMA update by June 2025?
2
Novo Nordisk•Ozempic•European Medicines Agency•EMA•Harvard University•Eli Lilly•Mounjaro•Britons•Wegovy
Resolution / Starting Odds
Kidney disease risk reduction • 25%
Weight management benefits • 25%
Diabetes management benefits • 25%
Other • 25%
Surveys or reports from healthcare providers and market analysts
Story
Novo Nordisk's Ozempic Label Update Approved by EMA for Risk Reduction of Kidney Disease-Related Events Amid Vision Loss Study
Dec 13, 2024, 01:46 PM
Novo Nordisk's diabetes drug Ozempic has received a positive opinion from the European Medicines Agency (EMA) to update its label, which will now reflect the drug's potential to reduce the risk of kidney disease-related events. This approval follows a study that found a small number of patients experienced vision loss linked to Ozempic, corroborating previous research from Harvard University. Concurrently, Eli Lilly's Mounjaro is gaining popularity among Britons seeking obesity treatments, surpassing Novo Nordisk's Wegovy in preference. The recent findings suggest that while Ozempic may offer significant benefits for weight management and diabetes, its association with rare vision loss raises important safety considerations for patients and healthcare providers alike.
View original story
Similar markets
Stricter guidelines issued • 25%
No changes • 25%
Guidelines relaxed • 25%
Guidelines under review • 25%
No action taken • 25%
Other regulatory actions • 25%
Product recall • 25%
Safety label update • 25%
Mounjaro • 25%
Wegovy • 25%
Ozempic • 25%
Other GLP-1 drug • 25%
Somewhat positive • 25%
Neutral • 25%
Negative • 25%
Highly positive • 25%
No decision made • 25%
Approve distribution city-wide • 25%
No distribution approved • 25%
Approve limited distribution • 25%
By Novo Nordisk • 25%
No campaigns • 25%
By both • 25%
By health organizations • 25%
Metabolic Liver Dysfunction • 25%
Diabetic Macular Edema • 25%
Other • 25%
Addiction Treatment • 25%